EGFR and non-small cell lung carcinoma: Prior to the publication of the ADAURA trial results (NCT02511106) in October 2023, osimertinib was primarily used as the standard first-line treatment for EGFR-mutated advanced NSCLC, with its use in the adjuvant setting not yet established [30,31].